Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3804-250A is a topical antiviral lotion developed by Dial Pharmaceuticals for the prevention of the common cold. The formulation is designed for application to the hands to prevent the transmission of rhinoviruses, which are the primary cause of the common cold. It functions by creating a persistent acidic environment on the skin that inactivates acid-labile viruses upon contact. The active ingredients typically include organic acids such as citric acid and malic acid, often in combination with surfactants like sodium lauryl sulfate. This approach aims to reduce infection rates by preventing the transfer of viruses from contaminated surfaces to the nasal or ocular mucosa.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3804-250A.